ATE552252T1 - Isochinolinverbindungen und deren medizinische verwendung - Google Patents

Isochinolinverbindungen und deren medizinische verwendung

Info

Publication number
ATE552252T1
ATE552252T1 AT03748659T AT03748659T ATE552252T1 AT E552252 T1 ATE552252 T1 AT E552252T1 AT 03748659 T AT03748659 T AT 03748659T AT 03748659 T AT03748659 T AT 03748659T AT E552252 T1 ATE552252 T1 AT E552252T1
Authority
AT
Austria
Prior art keywords
compound
cerebral infarction
agent
prophylaxis
treatment
Prior art date
Application number
AT03748659T
Other languages
English (en)
Inventor
Masakazu Fujio
Hiroyuki Satoh
Shinya Inoue
Toshifumi Matsumoto
Yasuhiro Egi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE552252T1 publication Critical patent/ATE552252T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
AT03748659T 2002-10-01 2003-10-01 Isochinolinverbindungen und deren medizinische verwendung ATE552252T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002288833 2002-10-01
JP2002340175 2002-11-22
JP2003109160 2003-04-14
PCT/JP2003/012608 WO2004031171A1 (ja) 2002-10-01 2003-10-01 イソキノリン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
ATE552252T1 true ATE552252T1 (de) 2012-04-15

Family

ID=32074144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748659T ATE552252T1 (de) 2002-10-01 2003-10-01 Isochinolinverbindungen und deren medizinische verwendung

Country Status (12)

Country Link
US (3) US7220759B2 (de)
EP (1) EP1557414B1 (de)
JP (1) JP4520406B2 (de)
KR (1) KR100735781B1 (de)
CN (1) CN100390164C (de)
AT (1) ATE552252T1 (de)
CA (1) CA2500888C (de)
DK (1) DK1557414T3 (de)
ES (1) ES2380917T3 (de)
PT (1) PT1557414E (de)
TW (1) TW200424188A (de)
WO (1) WO2004031171A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1557414E (pt) * 2002-10-01 2012-04-17 Mitsubishi Tanabe Pharma Corp Compostos de isoquinolina e sua utilização medicinal
US7501412B2 (en) * 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
AU2008287831B2 (en) * 2007-08-10 2013-05-23 Mitsubishi Tanabe Pharma Corporation Novel salt of isoquinoline compound and crystal thereof
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物
EP2729007A1 (de) 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
AU2013229229B2 (en) * 2012-03-07 2017-10-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
NO3044221T3 (de) 2013-09-11 2018-07-21
AR098776A1 (es) * 2013-12-18 2016-06-15 Chiesi Farm Spa Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
EP4053106A4 (de) * 2019-10-30 2023-12-06 Digmbio. Inc. Isochinolinonderivat, herstellungsverfahren dafür und dieses als wirkstoff enthaltende pharmazeutische zusammensetzung zur prävention oder behandlung von poly(adp-ribose)polymerase-1 (parp-1)-assoziierten krankheiten
CN113636970B (zh) * 2021-09-13 2023-05-23 河北康泰药业有限公司 一种异吲哚酮的化合物、制备方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1062357A (en) 1912-05-31 1913-05-20 Warschauer Schrauben Und Drahtfabriken Ag Nut-lock.
US1174272A (en) 1915-10-27 1916-03-07 Commw Steel Locomotive-bed.
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
JPS4612454Y1 (de) * 1968-07-26 1971-04-30
DE2121031A1 (en) 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
IT1054655B (it) 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS52156875A (en) 1976-06-23 1977-12-27 Mitsui Toatsu Chem Inc Preparation of novel isoquinolone derivatives
JPS5484597A (en) 1977-12-15 1979-07-05 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compound and its preparation
JPS6442472U (de) 1986-06-14 1989-03-14
US4808595A (en) 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
JPS6442472A (en) 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
DE68920798T2 (de) 1988-08-19 1995-05-18 Warner Lambert Co Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren.
WO1999008680A1 (en) 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
CA2332279A1 (en) * 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
EP1142881A4 (de) 1999-01-14 2003-05-07 Meiji Seika Kaisha Pyrimidinderivate als inhibitoren der poly(adp-ribose)-polymerase
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JPWO2001079184A1 (ja) 2000-04-18 2004-03-18 住友製薬株式会社 置換ピペラジン類
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
PT1557414E (pt) * 2002-10-01 2012-04-17 Mitsubishi Tanabe Pharma Corp Compostos de isoquinolina e sua utilização medicinal
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
JP4612454B2 (ja) 2005-03-31 2011-01-12 本田技研工業株式会社 ブレーキ制御装置

Also Published As

Publication number Publication date
WO2004031171A1 (ja) 2004-04-15
JP4520406B2 (ja) 2010-08-04
US7459465B2 (en) 2008-12-02
KR20050070024A (ko) 2005-07-05
KR100735781B1 (ko) 2007-07-06
EP1557414A4 (de) 2007-10-31
TWI338687B (de) 2011-03-11
DK1557414T3 (da) 2012-05-29
AU2003268724A1 (en) 2004-04-23
EP1557414A1 (de) 2005-07-27
CN100390164C (zh) 2008-05-28
US20070161620A1 (en) 2007-07-12
US20040248931A1 (en) 2004-12-09
CA2500888C (en) 2010-07-13
US7220759B2 (en) 2007-05-22
US7812178B2 (en) 2010-10-12
PT1557414E (pt) 2012-04-17
EP1557414B1 (de) 2012-04-04
ES2380917T3 (es) 2012-05-21
CN1703410A (zh) 2005-11-30
JPWO2004031171A1 (ja) 2006-02-02
TW200424188A (en) 2004-11-16
US20090076276A1 (en) 2009-03-19
CA2500888A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
TNSN04165A1 (en) Substituted hydroxyethylamines
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
NO20021691L (no) Benzodiazepinderivater
MY135841A (en) Novel benzodioxoles
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
SE0104332D0 (sv) Therapeutic agents
MXPA04000793A (es) Novedoso metodo terapeutico.
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
GB0225475D0 (en) Therapeutic agents
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
GB0318447D0 (en) Therapeutic agents
NO2007010I2 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
WO2000049007A8 (en) Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
HK1074046A1 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
ECSP055844A (es) Nuevos compuestos triciclicos
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
SE0202429D0 (sv) Novel Compounds
CA2341031A1 (en) Novel salt form of pantoprazole
ATE552252T1 (de) Isochinolinverbindungen und deren medizinische verwendung
ATE357453T1 (de) Comt-inhibitoren